SCHEMBL527397

SCHEMBL527397

COC(=O)c1cc([N+](=O)[O-])ccc1Br

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
MAPT P10636 6/20 0.49
POLB P06746 1/20 0.48
LMNA P02545 3/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
HTT P42858 4/20 0.46
PKM P14618 2/20 0.46
NPC1 O15118 2/20 0.46
CTSV O60911 1/20 0.46
CTSL P07711 1/20 0.46
HSP90AA1 P07900 1/20 0.46
PAX8 Q06710 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 1/20 0.44
SLC6A3 Q01959 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2721981 0.87 ALDH1A1 (0.49) ALDH1A1MAPTPOLBLMNAMEN1
SCHEMBL1403472 0.85 ALDH1A1 (0.56) ALDH1A1MAPTPOLBLMNAMEN1
SCHEMBL30203403 0.85 ALDH1A1 (0.56) ALDH1A1MAPTPOLBLMNAMEN1
SCHEMBL9068677 0.83 ALDH1A1 (0.54) ALDH1A1MAPTPOLBLMNAMEN1
Methane SCHEMBL27588822 0.83 ALDH1A1 (0.54) ALDH1A1MAPTPOLBLMNAMEN1
SCHEMBL25410674 0.83 NR3C2 (0.43) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL7790042 0.83 SMN1; SMN2 (0.60) ALDH1A1MAPTMEN1KMT2ANPC1
SCHEMBL391334 0.82 L3MBTL1 (0.62) ALDH1A1MAPTPOLBLMNAMEN1
SCHEMBL29448257 0.82 L3MBTL1 (0.62) ALDH1A1MAPTPOLBLMNAMEN1
SCHEMBL890895 0.82 ALDH1A1 (0.57) ALDH1A1MAPTPOLBLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 469 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6673930-B2 PREPARING A SELECTIVE GLUCOCORTICOID RECEPTOR AGENTS BY CYCLIZATION, DEHALOGENATION, AMINATION, ETHERIFICATION, HYDROXYLATION ABBVIE INC. 2004-01-06 US claimed
US-20030069427-A1 Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof ABBVIE INC. 2003-04-10 US claimed
WO-2003027117-A1 A PROCESS FOR THE PREPARATION OF 5-(SUBSTITUTED)-10-METHOXY-2,2,4-TRIMETHYL-2,5-DIHYDRO-1H-CHROMENO[3,4-F]QUINOLINES AND DERIVATIVES THEREOF ABBOTT LABORATORIES (US) 2003-04-03 WO claimed
US-6518430-B1 The present invention relates to an efficient process for the preparation of 5-(substituted)-10-methoxy-2,2,4-trimethyl-2,5- dihydro-1H-chromeno(3,4-f)quinolines. ABBOTT LABORATORIES 2003-02-11 US claimed
US-6306203-B1 FOR USE IN INK JET PRINTING, INCLUDING PIEZOELECTRIC INK JET PRINTING AND ACOUSTIC INK JET PRINTING XEROX CORPORATION 2001-10-23 US claimed
JP-10072449-A None JP disclosed
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF NEXYS THERAPEUTICS, INC. (US) 2026-01-22 US disclosed
EP-4081521-B1 SUBSTITUTED TRICYCLIC COMPOUNDS LUPIN LTD (IN) 2025-12-10 EP disclosed
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof NEXYS THERAPEUTICS, INC. (US) 2025-07-29 US disclosed
WO-2025096706-A1 MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-05-08 WO disclosed
WO-2025096771-A1 MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS BRISTOL-MYERS SQUIBB COMPANY (US) 2025-05-08 WO disclosed
EP-4522618-A1 TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS Merck Patent GmbH (DE) 2025-03-19 EP disclosed
US-5688808-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 US disclosed
US-5688810-A Steroid receptor modulator compounds and methods LIGAND PHARMACEUTICALS INCORPORATED (US) 1997-11-18 US disclosed
EP-0800519-A1 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS, INC. (US) 1997-10-15 EP disclosed
WO-1997036859-A1 PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-10-09 WO disclosed
WO-1997036860-A1 CINNAMIC ACID DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-10-09 WO disclosed
WO-1996033175-A1 CYCLIC AMIDINO AGENTS USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1996-10-24 WO disclosed
WO-1996019458-A2 STEROID RECEPTOR MODULATOR COMPOUNDS AND METHODS LIGAND PHARMACEUTICALS INCORPORATED (US) 1996-06-27 WO disclosed
US-4102924-A REACTING ACYLAMINO-ARYLS WITH HALO-ARYLS BAYER AKTIENGESELLSCHAFT (DE) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069427-A1 Process for the preparation of 5-(substituted)-10 methoxy-2,2,4-trimethyl-2,5-dihydro- 1H-chromeno [3,4-f] quinolines and derivatives thereof HTR3C, CYP3A5, NQO2 ALDH1A1 1684/4885MAPT 3327/4885POLB 2227/4885
US-12371408-B2 Aryl hydrocarbon receptor agonists and uses thereof AHR, ARNT, NR1H2 ALDH1A1 602/4885MAPT 1282/4885POLB 3688/4885
US-20260022099-A1 ARYL HYDROCARBON RECEPTOR AGONISTS AND USES THEREOF AHR, NR1H4, CNR1 ALDH1A1 807/4885MAPT 1624/4885POLB 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.